Our Milestones

Date Milestone

June 2002

Phoenix Eagle Company Pty Ltd founded

July 2002

Provisional patent application filed in Australia

July 2003

PCT (Patent Co-operation Treaty) patent application filed

July 2005

Quadriplegic Centre Report issued –Successful outcomes in the treatment of non-healing pressure ulcers in a Perth hospital from use of OPAL A

Apr 2006

First patent granted – in South Africa – without examination

Feb 2008

First patent granted after examination – in New Zealand (after 4 examinations)

May 2008

Publication of manuscript by Associate Professor Nick Graves of Queensland University of Technology and Dr Elaine Ashby, Senior Medical Consultant of the Taku Group, California, in Wound Practice and Research describing the clinical use of OPAL A in the Quadriplegic Centre, Perth

May 2008

Presentation by Associate Professor Geffrey Mitchell of The University of Queensland School of Medicine at the Australian Wound Management Association Conference in Darwin on OPAL A, entitled “Alkalised fruit extract as a potential treatment for chronic ulcers.”

Dec 2008

Australian patent granted

July 2009

Engagement of Emeritus Professor Keith Brocklehurst and Professor Michael Philpott of Queen Mary College, The University of London to undertake research into the proteolytic activity of the cysteine proteases in OPAL A

Feb 2010

Commencement of a proof-of-concept clinical trial for the use of OPAL A in the treatment of venous and pressure ulcers at the Heidelberg Repatriation Hospital in Melbourne

July 2010

Appointment of Professor Michael Philpott, lead of the Centre for Cutaneous Research at the Blizard Institute in London, to direct and manage an ongoing program of scientific studies into the properties of OPAL A

Oct 2010

Award of a scholarship for a Ph D, supervised by Professor Michael Philpott, to Sreekanth Vootukuri Reddy to investigate the active molecules in OPAL A and their activities

Sep 2011

Professor Geoffrey Mitchell granted Authorised Prescriber status by the TGA for the use of OPAL A as an unapproved therapeutic good to treat non-healing venous and pressure ulcers

July 2012

First U.S. patent issued

Nov 2013

Associate Professor Michael Woodward granted Authorised Prescriber status by the TGA for the use of OPAL A as an unapproved therapeutic good to treat non-healing venous and pressure ulcers

A number of important milestones relating to the discoveries and inventions made in the course of the work at Queen Mary University of London (as Queen Mary and Westfield College was renamed) have been achieved during the last 5 years, which will be the subject of second generation patent applications. At present this valuable Intellectual Property is Confidential.

Contact Us

Phoenix Eagle Company Pty Ltd
Suite 5
531 Hay Street
Subiaco, WA 6008
Australia
Tel: 0419 094 748
Email: business@phoenixeaglecompany.com

Quick Links